Fjarde AP Fonden Fourth Swedish National Pension Fund Lowers Holdings in Solventum Co. (NYSE:SOLV)

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in Solventum Co. (NYSE:SOLV) by 6.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,584 shares of the company’s stock after selling 1,800 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Solventum were worth $1,756,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Worldquant Millennium Advisors LLC lifted its stake in shares of Solventum by 373.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after purchasing an additional 9,333 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Solventum by 37.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares during the last quarter. State Street Corp lifted its stake in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Finally, Forsta AP Fonden purchased a new stake in shares of Solventum during the 4th quarter worth $1,876,000.

Solventum Price Performance

Shares of SOLV stock opened at $83.83 on Thursday. The stock’s 50-day simple moving average is $71.92 and its 200-day simple moving average is $69.63. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $71.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.